Drug Usage Analysis and Health Care Resources Consumption in Patients With Rheumatoid Arthritis

Abstract

A373vs. 7% (range: 0% (Germany/Spain) -25% (UK)). Latest disease severity measures documented were (adalimumab vs. etanercept): Swollen Joint Counts: 1.6 (range: 0.4 (Spain) -2.9 (UK)) vs. 2.7 (1.4 (Germany) -8.0 (UK)), Tender Joint Counts: 2.4 (range: 0.9 (Spain) -3.5 (Italy)) vs. 4.1 (range: 1.9 (Germany) -9.8 (UK)), and HAQ rating: 1.2 (range: 0.4 (Spain) -2.7 (Germany)) vs. 1.5 (range: 1.3 (Germany) -2.0 (France)). ConClusions: Among PsA patients receiving adalimumab or etanercept monotherapy, disease severity differed within the EU5, with patients on etanercept, and patients in Italy and UK, having relatively higher burden and poorer outcomes. Factors influencing the observed patterns of geographic variation and the impact of specific biologic treatments on observed patterns warrant further scrutiny to optimize therapeutic interventions and improve outcomes.